GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Influenza

Phase 1

Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults

CompletedNCT01059617

GlaxoSmithKlineInfluenza

Start: 2010-02-09End: 2011-10-21Updated: 2018-08-20

Phase 2

Safety and Immune Response of One-Dose of Candidate H1N1 Influenza Vaccine GSK2340274A in Adults

WithdrawnNCT01008956

GlaxoSmithKlineInfluenza

Start: 2010-04-30End: 2010-10-31Updated: 2015-03-23

Related Papers

Responses to A(H1N1)pdm09 Influenza Vaccines in Participants Previously Vaccinated With Seasonal Influenza Vaccine: A Randomized, Observer-Blind, Controlled Study

The Journal of Infectious Diseases2014-05-2621 citations